Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5435573 | 0.93 | SIGMAR1 (0.40) | SIGMAR1KDM4ESMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL5433734 | 0.92 | SIGMAR1 (0.40) | SIGMAR1KDM4ESMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL5433728 | 0.92 | SIGMAR1 (0.40) | SIGMAR1KDM4ESMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL4136760 | 0.90 | DDB1 (0.38) | DDB1CRBNSIGMAR1HRH3PARP1 | |
| SCHEMBL4143498 | 0.88 | KDM4E (0.52) | DDB1CRBNSIGMAR1KDM4ESMN1; SMN2 | |
| SCHEMBL4143494 | 0.88 | KDM4E (0.52) | DDB1CRBNSIGMAR1KDM4ESMN1; SMN2 | |
| SCHEMBL3975810 | 0.87 | MTNR1A (0.41) | SIGMAR1KDM4ESMN1; SMN2CYP1A2P2RY14 | |
| SCHEMBL4136252 | 0.85 | KDM4E (0.33) | DDB1CRBNKDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL5433730 | 0.84 | SIGMAR1 (0.37) | SIGMAR1SMN1; SMN2CYP1A2CNR2 | |
| SCHEMBL4169255 | 0.82 | SIGMAR1 (0.38) | SIGMAR1GSK3BP2RY14CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111760-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-04-30 | — | — | US | disclosed |
| EP-1824869-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006050941-A1 | MACROLONE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111760-A1 | MACROLONE COMPOUNDS | CYP51A1, MRPL21, MYD88 | DDB1 3765/4885CRBN 3533/4885SIGMAR1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.